{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T05:14:11Z","timestamp":1762838051201,"version":"build-2065373602"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to evaluate the impact of pre-existing cardiovascular disease (CVD) and dyslipidemia on mortality in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was conducted as a multicenter retrospective cohort investigation. Eligible patients newly diagnosed with CAPD between January 1, 2005 and December 31, 2018 were enrolled in this study. Missing data were handled using the missForest imputation method. The primary outcome was all-cause mortality. All patients were followed until the cessation of peritoneal dialysis, death, completion of the 8-year follow-up period, or June 30, 2019, whichever occurred first.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the 2939 patients, 2132 (72.5%) had no pre-existing CVD or hyperlipidemia, 397 (13.5%) had hyperlipidemia alone, 274 (9.3%) had pre-existing CVD alone, and 136 (4.6%) had pre-existing CVD and hyperlipidemia. The median observational period was 33.6 (IQR 15.6\u201360.8) months. The number of deaths from all causes were 72 (36.8%), 67 (16.9%), 96 (35.0%), and 306 (14.4%) in the pre-existing CVD plus hyperlipidemia, hyperlipidemia alone, pre-existing CVD alone, and control groups, respectively. After adjusting for confounding factors, patients with pre-existing CVD alone, hyperlipidemia alone, and patients with both conditions had 1.41 (95% CI 1.03 to 1.94), 0.98 (95% CI 0.75 to 1.28) and 1.47 (95% CI 1.16-1.88)-fold greater risk of all-cause mortality, respectively, than patients without pre-existing CVD and hyperlipidemia. Notably, among patients with pre-existing CVD, hyperlipidemic patients had a higher risk of mortality than patients without hyperlipidemia (hazard ratio 0.89, 95% CI 0.61 to 1.31). Among patients without pre-existing CVD, hyperlipidemic patients had a higher risk of mortality than patients without hyperlipidemia (HR 1.10, 95% CI 0.83 to 1.48). There was no interaction effect between the coexistence of pre-existing CVD and hyperlipidemia, pre-existing CVD alone, and hyperlipidemia alone on all-cause mortality (\n                      <jats:italic>\u03b2<\/jats:italic>\n                      \u00a0=\u00a00.221,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.976).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients undergoing CAPD, the coexistence of pre-existing cardiovascular disease and hyperlipidemia is associated with a significantly higher risk of all-cause mortality. This finding suggests that the comorbidity may contribute to worse long-term outcomes and highlights the importance of dyslipidemia management in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1693668","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T05:11:06Z","timestamp":1762837866000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Pre-existing cardiovascular disease and hyperlipidemia and mortality in peritoneal dialysis patients"],"prefix":"10.3389","volume":"16","author":[{"given":"Panpan","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojiang","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueqiang","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoran","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenfen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianfeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2019.0375","article-title":"Risk of cardiovascular disease and mortality in young adults with end-stage renal disease: an analysis of the US renal data system","volume":"4","author":"Modi","year":"2019","journal-title":"JAMA Cardiol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.0000000000000418","article-title":"Complications of peritoneal dialysis part II: nonmechanical complications","volume":"19","author":"Cheng","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2014.00030","article-title":"Patient survival and technique failure in continuous ambulatory peritoneal dialysis patients with prior stroke","volume":"36","author":"Wu","year":"2016","journal-title":"Perit Dial Int"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2021.03.016","article-title":"2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcvp\/pvae058","article-title":"Management of dyslipidaemia in patients with comorbidities: facing the challenge","volume":"10","author":"Mayer","year":"2024","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3109\/0886022X.2015.1061871","article-title":"Meta-analysis of statin therapy in maintenance dialysis patients","volume":"37","author":"Sun","year":"2015","journal-title":"Ren Fail"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26073376","article-title":"The clinical utility and plausibility of oxidative and antioxidant variables in chronic and end-stage kidney disease: A review of the literature","volume":"26","author":"Tsinari","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"B9","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/s12882-022-02970-w","article-title":"Hyperlipidemia and mortality in patients on peritoneal dialysis","volume":"23","author":"Feng","year":"2022","journal-title":"BMC Nephrol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2016.08.016","article-title":"Guidelines for the management of hypertension","volume":"101","author":"Chobanian","year":"2017","journal-title":"Med Clin North Am"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-3758.2016.10.005","article-title":"2016 Chinese guideline for the management of dyslipidemia in adults","volume":"44","year":"2016","journal-title":"Zhonghua Xin Xue Guan Bing Za Zhi"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60033-6","article-title":"Prevalence of chronic kidney disease in China: a cross-sectional survey","volume":"379","author":"Zhang","year":"2012","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1186\/s12882-017-0687-2","article-title":"Renal Association Clinical Practice Guideline on peritoneal dialysis in adults and children","volume":"18","author":"Graham","year":"2017","journal-title":"BMC Nephrol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2011.11.015","article-title":"'United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States","volume":"59","author":"Collins","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1186\/s12944-020-01405-5","article-title":"Hyperlipidemia and mortality associated with diabetes mellitus co-existence in Chinese peritoneal dialysis patients","volume":"19","author":"Wei","year":"2020","journal-title":"Lipids Health Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/IJNRD.S101808","article-title":"Dyslipidemia in patients with chronic kidney disease:etiology and management","volume":"10","author":"Ivana","year":"2017","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1186\/s12882-025-04417-4","article-title":"Effects of different peritoneal dialysis solutions on serum lipid levels and lipid profile in end-stage chronic kidney disease patients undergoing peritoneal dialysis","volume":"26","author":"Aydin","year":"2025","journal-title":"BMC Nephrol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1671-2390.2023.03.001","article-title":"Effects of diabetes or new onset hyperglycemia on prognosis in peritoneal dialysis patients","volume":"23","author":"Du","year":"2023","journal-title":"J Clin Nephrology"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1116103","article-title":"Chinese experience on comparison of clinical efficacy and safety of hemodialysis and peritoneal dialysis in the treatment of diabetic kidney failure: a systematic review and meta-analysis","volume":"10","author":"Wei","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2003.11.008","article-title":"Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis","volume":"43","author":"Vernaglione","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/089686080702700313","article-title":"Anti-inflammatory effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) in peritoneal dialysis patients","volume":"27","author":"Kumar","year":"2007","journal-title":"Perit Dial Int"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2002.33393","article-title":"Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients","volume":"39","author":"Chang","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41401-022-00947-x","article-title":"Integrative phosphatidylcholine metabolism through phospholipase A2 in rats with chronic kidney disease","volume":"44","author":"Wang","year":"2023","journal-title":"Acta Pharmacol Sin"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-025-01476-z","article-title":"Cardiorenal syndrome: clinical diagnosis, molecular mechanisms and therapeutic strategies","volume":"46","author":"Zhao","year":"2025","journal-title":"Acta Pharmacol Sin"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/909373","article-title":"Clinical causes of inflammation in peritoneal dialysis patients","volume":"2014","author":"Yeoungjee","year":"2014","journal-title":"Int J Nephrol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.freeradbiomed.2023.07.014","article-title":"Oxidative stress and inflammation are mediated via aryl hydrocarbon receptor signalling in idiopathic membranous nephropathy","volume":"207","author":"Wang","year":"2023","journal-title":"Free Radic Biol Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-023-01148-w","article-title":"Sirtuin 6 protects against podocyte injury by blocking the renin-angiotensin system by inhibiting the Wnt1\/\u03b2-catenin pathway","volume":"45","author":"Miao","year":"2024","journal-title":"Acta Pharmacol Sin"},{"key":"B28","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/s00018-024-05532-5","article-title":"Gut microbiota regulates oxidative stress and inflammation: a double-edged sword in renal fibrosis","volume":"81","author":"Li","year":"2024","journal-title":"Cell Mol Life Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.996166","article-title":"Dietary choline, via gut microbe- generated trimethylamine-N- oxide, aggravates chronic kidney disease-induced cardiac dysfunction by inhibiting hypoxia-induced factor 1\u03b1","volume":"13","author":"Xie","year":"2022","journal-title":"Front Physiol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"182","DOI":"10.5527\/wjn.v12.i5.182","article-title":"Heterogeneity in cardiorenal protection by Sodium glucose cotransporter 2 inhibitors in heart failure across the ejection fraction strata: Systematic review and meta-analysis","volume":"12","author":"Taheri","year":"2023","journal-title":"World J Nephrol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1693668\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T05:11:08Z","timestamp":1762837868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1693668\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":30,"alternative-id":["10.3389\/fendo.2025.1693668"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1693668","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"article-number":"1693668"}}